Human immunodeficiency virus-1 B and non-B subtypes with the same drug resistance pattern respond similarly to antiretroviral therapy

被引：6

作者：

Franzetti, M. ^{[1
]}

Violin, M. ^{[1
]}

Casazza, G. ^{[2
]}

Meini, G. ^{[3
]}

Callegaro, A. ^{[4
]}

Corsi, P. ^{[5
]}

Maggiolo, F. ^{[6
]}

Pignataro, A. R. ^{[7
]}

Paolucci, S. ^{[8
]}

Gianotti, N. ^{[9
]}

Francisci, D. ^{[10
]}

Rossotti, R. ^{[11
]}

Filice, G. ^{[12
]}

Carli, T. ^{[13
]}

Zazzi, M. ^{[3
]}

Balotta, C. ^{[1
]}

机构：

[1] Univ Milan, Sect Infect Dis & Immunopathol, Dept Clin Sci L Sacco, Milan, Italy

[2] Univ Milan, Unit Stat & Biometry, Milan, Italy

[3] Univ Siena, Dept Biotechnol, I-53100 Siena, Italy

[4] Osped Riuniti Bergamo, Dept Microbiol & Virol, Bergamo, Italy

[5] Careggi Hosp, Dept Infect Dis, Florence, Italy

[6] Osped Riuniti Bergamo, Dept Infect Dis, Bergamo, Italy

[7] Ist Sci San Raffaele, Dept Virol, I-20132 Milan, Italy

[8] Fdn IRCCS Policlin San Matteo, Mol Virol Unit, Pavia, Italy

[9] Ist Sci San Raffaele, Dept Infect Dis, I-20132 Milan, Italy

[10] Univ Perugia, Infect Dis Clin, I-06100 Perugia, Italy

[11] A Manzoni Hosp, Infect Dis Clin, Lecce, Italy

[12] Fdn IRCCS Policlin San Matteo, Dept Infect Dis, Pavia, Italy

[13] Misericordia Hosp, Dept Infect Dis, Grosseto, Italy

来源：

CLINICAL MICROBIOLOGY AND INFECTION | 2012年 / 18卷 / 03期

关键词：

Antiretroviral treatment; drug resistance; HIV-1; evolution; non-B subtypes; REVERSE-TRANSCRIPTASE; HIV-1; SUBTYPES; PROTEASE; PREVALENCE; IMPACT; STRAINS; NAIVE;

D O I：

10.1111/j.1469-0691.2011.03740.x

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

We analysed the 12-week virological response to protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) therapy in 1108 patients carrying B or non-B human immunodeficiency virus (HIV)-1 subtypes with matched resistance mutation patterns. Response rates were not significantly different for non-B and B subtypes stratified for treatment status (51.5% vs. 41.5% in naive patients; 46.7% vs. 38.7% in experienced patients) or regimens (46.9% vs. 39.7% with PI; 56.7% vs. 40% with NNRTI). No difference in response was detected in patients harbouring B and non-B subtypes with any resistance profile. Further studies are advisable to fully test this approach on larger datasets.

引用

下载

页码：E66 / E70

页数：5

共 50 条

[21] Study of the mutations associated to integrase inhibitor resistance in subtype B and non-B human immunodeficiency virus type 1
Montagna, C.
Falasca, F.
Bucci, M.
Lichtner, M.
Russo, G.
Sobze, M. Sanou
Scagnolari, C.
Antonelli, G.
Turriziani, O.
INFECTION, 2010, 38 : 56 - 56
[22] Expanded evaluation of blood donors in the United States for human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains: 2005 through 2007
Brennan, Catherine A.
Yamaguchi, Julie
Devare, Sushil G.
Foster, Greg A.
Stramer, Susan L.
TRANSFUSION, 2010, 50 (12) : 2707 - 2712
[23] Performance of drug resistance assays in testing HIV-1 non-B subtypes
Holguín, A
Hertogs, K
Soriano, V
CLINICAL MICROBIOLOGY AND INFECTION, 2003, 9 (04) : 323 - 326
[24] Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients
Epaulard, Olivier
Signori-Schmuck, Anne
Larrat, Sylvie
Kulkarni, Om
Blum, Michael G.
Fusillier, Katia
Blanc, Myriam
Leclercq, Pascale
Francois, Olivier
Morand, Patrice
JOURNAL OF CLINICAL VIROLOGY, 2017, 95 : 13 - 19
[25] Epidemiological surveillance of the transmission of antiretroviral drug resistant strains and the introduction of non-B subtypes
Garcia, Federico
Guillot, Vicente
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2011, 29 (07): : 479 - 481
[26] Differential first-line antiretroviral therapy resistance in HIV-1 non-B subtypes in India, China and Thailand
Huang, A.
Katzenstein, D. A.
Saravanan, S.
Wu, Y.
Sirivichayakul, S.
Kumarasamy, N.
Zhang, F.
Phanuphak, P.
Kantor, R.
ANTIVIRAL THERAPY, 2013, 18 : A75 - A75
[27] Epidemiological, Clinical and Antiretroviral Susceptibility Characterization of Human Immunodeficiency Virus Subtypes B and Non-B in Pernambuco, Northeast Brazil (vol 11, e0155854, 2016)
Lima, Kledoaldo
Leal, Elcio de Souza
Salustiano Cavalcanti, Ana Maria
Salustiano, Daniela Medeiros
de Medeiros, Luzidalva Barbosa
da Silva, Sirleide Pereira
Lacerda, Heloisa Ramos
PLOS ONE, 2016, 11 (06):
[28] Molecular epidemiology of vertical human immunodeficiency virus type I transmission in Greece: Evidence of non-B subtypes
Paraskevis, D
Magiorkinis, E
Theodoridou, M
Mostrou, G
Papaevangelou, V
Kiosses, VG
Hatzakis, A
Matsaniotis, N
JOURNAL OF HUMAN VIROLOGY, 1999, 2 (06) : 339 - 343
[29] Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia
Alexander, CS
Montessori, V
Wynhoven, B
Dong, W
Chan, K
O'Shaughnessy, MV
Mo, T
Piaseczny, M
Montaner, JSG
Harrigan, PR
ANTIVIRAL THERAPY, 2002, 7 (01) : 31 - 35
[30] Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance
Sethi, AK
Celentano, DD
Gange, SJ
Moore, RD
Gallant, JE
CLINICAL INFECTIOUS DISEASES, 2003, 37 (08) : 1112 - 1118

← 1 2 3 4 5 →